Explore the words cloud of the IMPEDE project. It provides you a very rough idea of what is the project "IMPEDE" about.
The following table provides information about the project.
UNIVERSITA DEGLI STUDI DI VERONA
|Coordinator Country||Italy [IT]|
|Total cost||150˙000 €|
|EC max contribution||150˙000 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2016-02-01 to 2017-07-31|
Take a look of project's partnership.
|1||UNIVERSITA DEGLI STUDI DI VERONA||IT (VERONA)||coordinator||150˙000.00|
Auto-immune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA) and inflammation-associated brain diseases including Alzheimer's disease (AD) globally make up a €45B market and cost society close to €648B. The huge number of patients with these diseases causes an enormous socioeconomic burden. Currently, MS, AD and RA affect 120M people worldwide. There is no cure for AD and treatments for autoimmune diseases are not fully effective and reducing the inflammatory component in these diseases is a key strategy. As a result of our ERC StG NEUROTRAFFICKING we found that a natural molecule, which is Coenzyme A precursor (CoAP), modulates leukocyte trafficking and has anti-inflammatory properties that are, however, limited in effectiveness due to fast breakdown in the gut. Our preliminary data demonstrate that derivatives of CoAP hydrolysis are devoid of antiinflammatory effects and that intact CoAP is required for its therapeutic effect in mouse models of MS and AD. The goal of IMPEDE is to develop a proprietary formulation of CoAP that protects it from hydrolysis and its disulphide bonds from degradation. This provides a novel and highly promising therapeutic approach for the inflammatory diseases, either for combination or stand-alone treatment. A patent application for this novel CoAP formulation has been filed. Subsequent steps will be taken in IMPEDE to generate and validate a more effective product through improved formulation and to prepare further regulatory and IP strategies, design a business strategy and perform market research. Overall, IMPEDE offers a rapid valorisation of the ERC StG grant on one hand and of the novel CoAP formulation on the other hand. It will generate a novel CoAP formulation with high therapeutic potential in autoimmune diseases and other inflammatory diseases.
|year||authors and title||journal||last update|
Elena Zenaro, Gennj Piacentino, Gabriela Constantin
The blood-brain barrier in Alzheimer\'s disease
published pages: 41-56, ISSN: 0969-9961, DOI: 10.1016/j.nbd.2016.07.007
|Neurobiology of Disease 107||2019-07-22|
Enrica Caterina Pietronigro, Vittorina Della Bianca, Elena Zenaro, Gabriela Constantin
NETosis in Alzheimerâ€™s Disease
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2017.00211
|Frontiers in Immunology 8||2019-07-22|
Barbara Rossi, Gabriela Constantin
Live Imaging of Immune Responses in Experimental Models of Multiple Sclerosis
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2016.00506
|Frontiers in Immunology 7||2019-07-22|
Enrica Pietronigro, Elena Zenaro, Gabriela Constantin
Imaging of Leukocyte Trafficking in Alzheimerâ€™s Disease
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2016.00033
|Frontiers in Immunology 7||2019-07-22|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMPEDE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IMPEDE" are provided by the European Opendata Portal: CORDIS opendata.